🔎 Trials Near Me

Akèy › Neoplazmi myeloproliferatif › Massachusetts

Etid klinik pou Neoplazmi myeloproliferatif nan Massachusetts

15 etid pou Neoplazmi myeloproliferatif ap chèche patisipan nan sit nan Massachusetts.

Vil nan Massachusetts

Tèks ofisyèl etid la (Anglè)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Tufts Medical Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
  • ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Tufts Medical Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
  • ak 2 plis
Ap rekriteFaz 2
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03471260

Project: Every Child for Younger Patients With Cancer

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
  • Baystate Medical Center, Springfield
  • ak 1 plis
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244

Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis

  • Mass General Brigham, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT07249840

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

  • Brigham and Women's Hospital, Boston
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07020533

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

  • Boston Children's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 12 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT04024761

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT06138587

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  • Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT06034002

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

  • DFCI/BWH Brigham and Women's Hospital, Boston
Ap rekriteFaz 2Volontè an sante akeyi
Laj 18 a 75 · Tout sèks · Mizajou Mar 10, 2026 · NCT06059391

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Worcester
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Massachusetts General Hospital Cancer Center, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT05842603

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.